Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* body weight 40-100kg~* diagnosed as systemic lupus erythematosus, (according to American College of Rheumatology Diagnostic Criteria,1997)~* diagnosed as type III/ IV of lupus nephritis by renal biopsy within 6 months~* 24hr proteinuria ≥2g and/or active urinary sediments~Exclusion Criteria:~* receiving immunosuppressant~* receiving routine treatment of tacrolimus and leflunomide within 1 month~* receiving nonsteroidal anti-inflammatory drugs (NSAIDs) within 1 months before the study~* history of allergy to tacrolimus and leflunomide~* anticipated maintenance dialysis persisted over 8 weeks; or already being dialyzed over 2 weeks before recruitment~* planning to receive kidney transplantation or in the near future or having a history of undergoing kidney transplantation~* serum creatinine (Scr) ≥3mg/dl or estimated glomerular filtration rate (eGFR) \< 30ml/min~* diabetes mellitus patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- tacrolimus group (Type: EXPERIMENTAL): tacrolimus capsule + leflunomide placebo
- leflunomide group (Type: ACTIVE_COMPARATOR): tacrolimus placebo + leflunomide tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).